The US Food and Drug Administration (FDA) has accepted for review the biologics license application (BLA) for MK-8237, Merck's house dust mite sublingual allergy immunotherapy (SLIT) tablet.

Merck’s house dust mite SLIT-tablet is an investigational sublingual immunotherapy dissolvable tablet designed to help treat allergic rhinitis with or without conjunctivitis caused by house dust mite-specific allergens. Merck has partnered with ALK-Abelló, a Danish pharmaceutical company, to develop its house dust mite SLIT-tablet in North America.

Source: Merck & Co.